KF2019#1-trial: Effects of a Thrombocyte Inhibitor on a Cholesterol-lowering Drug
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The cholesterol-lowering drug rosuvastatin is a substrate of the breast cancer resistance
protein (BCRP). BCRP is an efflux transporter expressed e.g. in the small intestine. It
limits the oral bioavailability of rosuvastatin by transporting rosuvastatin from enterocytes
back to the gut lumen. Inhibition of BCRP can increase rosuvastatin bioavailability and
systemic concentrations. Ticagrelor is a platelet aggregation inhibitor used in treatment and
prevention of atherothrombotic events. Ticagrelor may inhibit BCRP in humans. This study is
aimed to investigate the possible interaction of rosuvastatin with ticagrelor. Ten healthy
male or female non-smoking volunteers aged 18-40 years are taken into the study. Primary
endpoint is area under the plasma concentration-time curve of rosuvastatin.